Skip to main content

Table 3 Independent predictors of 90-day mortality in elderly solid tumor patients (n = 262)

From: Outcomes in elderly patients admitted to the intensive care unit with solid tumors

  Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age (HR for increase of 1 year) 0.98 (0.95–1.01) 0.16 0.99 (0.95–1.03) 0.57
Sex     
 Male 1   1  
 Female 0.66 (0.46–0.96) 0.03 0.75 (0.43–1.30) 0.30
Performance status     
 0–1 1 0.07 1 0.17
 2 1.30 (0.85–1.97)   1.58 (0.97–2.59)  
 3–4 1.88 (1.10–3.23)   1.53 (0.77–3.05)  
Primary tumor site
 Genitourinary 1 0.005 1 0.01
 Gastrointestinal 1.10 (0.65–1.86)   0.96 (0.49–1.89)  
 Breast 0.82 (0.36–1.89)   0.38 (0.11–1.27)  
 Lung 1.37 (0.83–2.26)   1.11 (0.59–2.08)  
 Head and neck 2.60 (1.49–4.53)   2.69 (1.25–5.79)  
 Other 0.75 (0.29–1.96)   0.80 (0.24–2.67)  
Metastatic status
 No 1   1  
 Yes 0.96 (0.68–1.36) 0.82 1.61 (0.98–2.59) 0.06
Number of previous systemic anti-tumoral treatments 0.88 (0.73–1.07) 0.19 (–)  
Reason for ICU admission     
 Not related to cancer 1 (–) 0.68 1 0.50
 Related to anticancer drugs 1.07 (0.69–1.67)   0.87 (0.49–1.52)  
 Related to cancer progression 1.23 (0.76–2.00)   1.23 (0.66–2.28)  
SAPS 2 score (HR for increase of 1 unit) 1.05 (1.04–1.06) <0.0001 1.05 (1.03–1.06) <0.0001
Life-support techniques     
 Mechanical ventilation use 5.96 (3.91–9.10) <0.0001 (–)  
 Noninvasive ventilation use 0.81 (0.46–1.44) 0.48 (–)  
 Inotropes use 3.68 (2.54–5.33) <0.0001 (–)  
 Dialysis use 1.28 (0.79–2.08) 0.32 (–)  
Limitation of active therapies during ICU stay 3.79 (2.59–5.56) <0.0001 (–)  
Laboratory findings (HR for increase of 1 unit)     
 Albumin 0.94 (0.89–0.99) 0.02 (–)  
 Leukocytes 1.01 (1.01–1.02) <0.0001 0.99 (0.97–1.01) 0.57
 Glycemia 1.03 (1.00–1.05) 0.04 1.01 (0.98–1.06) 0.46
 pH 0.04 (0.01–0.13) <0.0001 0.85 (0.16–4.41) 0.84
 Lactates 1.18 (1.13–1.22) <0.0001 1.07 (0.99–1.15) 0.08
 ASAT 1 (1–1.001) <0.0001 1 (1–1) 0.58
  1. ASAT aspartate aminotransferase, CI confidence interval, HR hazard ratio